How do reagent-rental contracts affect total cost of ownership for POC molecular analyzers?

Reagent-rental agreements eliminate upfront capital expenditure by bundling instrument access into per-test pricing, typically adding USD 3–8 per cartridge above list price. Facilities running more than 15 tests per day generally achieve lower total cost through outright purchase [17]. Read More

What specimen types beyond nasopharyngeal swabs are gaining traction on POC molecular platforms?

Whole blood, urine, and rectal swabs are expanding platform utility into sepsis, urinary-tract-infection, and STI workflows. Saliva-based collection is also under active FDA review for respiratory panels [9]. Read More

How does POC molecular testing integrate with electronic health record systems?

Most current-generation analyzers support HL7 and FHIR data standards for bidirectional EHR connectivity. Successful integration reduces manual transcription errors and enables automated result-triggered clinical-decision-support alerts [10]. Read More

What role do contract-development organizations play in cartridge manufacturing scale-up?

CDMOs provide lyophilization, fill-finish, and quality-control capacity that smaller diagnostics companies lack in-house. Outsourced manufacturing shortened time-to-market by an average of nine months during the 2023–2024 product cycle [18]. Read More

How are antimicrobial-resistance gene panels differentiated from standard pathogen-ID panels?

Resistance panels detect genotypic markers such as mecA and carbapenemase genes alongside organism identification. This dual output enables targeted antibiotic selection within 45 minutes rather than awaiting 48-hour culture-based susceptibility results [16]. Read More

What cybersecurity risks emerge from cloud-connected POC molecular instruments?

Connected analyzers transmit patient-identifiable data to cloud dashboards, exposing facilities to HIPAA-relevant breach risk. Manufacturers are adopting zero-trust architectures and end-to-end encryption to mitigate these vulnerabilities [10]. Read More

Can POC molecular platforms support veterinary diagnostic applications?

Several cartridge-based systems have received USDA validation for canine parvovirus and equine influenza detection. Veterinary applications remain a niche but growing adjacency valued at approximately USD 85 Million globally in 2024 [1]. Read More

Point of Care Molecular Diagnostics Market (2026 - 2035)

Point of Care Molecular Diagnostics Market Research Report: Size, Share, Trend Analysis By Product Type (PCR Tests, Nucleic Acid Amplification Tests, Microarray, Next-Generation Sequencing, Other Genetic Tests), By Applications (Infectious Diseases, Genetic Testing, Cancer Diagnosis, Metabolic Disorders), By End Use (Hospitals, Diagnostic Laboratories, Home Care Settings, Outpatient Clinics), By Technology (Isothermal Amplification, Polymerase Chain Reaction, Sanger Sequencing, CRISPR Technology) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2026-2035

CAGR

10.5%

2025 Market Size

USD 4.58 Billion

2035 Market Size

USD 12.44 Billion

Healthcare ● Updated August 2026 Report ID: MRFR/HC/9964-HCR | Pages: 200 | Author: Rahul Gotadki, Vikita Thakur

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Overview |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Market Summary & Key Takeaways
3 Market Dynamics |
1. 3.1 Market Drivers Analysis | |
  1. 3.1.1 CLIA-Waiver Expansion for Molecular Panels | |
  2. 3.1.2 BARDA & Public-Health Stockpiling Programs | |
  3. 3.1.3 IVDR & EU Regulatory Harmonization | |
  4. 3.1.4 TB & HIV Elimination Campaigns in LMIC | |
  5. 3.1.5 AI-Enabled Remote Instrument Monitoring | |
  6. 3.1.6 Multiplex Panel Innovation | |
  7. 3.1.7 Reimbursement Pathway Reforms |
2. 3.2 Market Restraints Analysis | |
  1. 3.2.1 High Upfront Instrument Capital Cost | |
  2. 3.2.2 Limited Test-Menu Breadth vs. Central Labs | |
  3. 3.2.3 Reimbursement Uncertainty in Emerging Markets | |
  4. 3.2.4 Quality-Control Complexity in Non-Laboratory Settings | |
  5. 3.2.5 Supply-Chain Concentration for Reagent Raw Materials |
3. 3.3 Market Opportunity Analysis | |
  1. 3.3.1 Pharmacogenomic Testing at the Prescribing Point | |
  2. 3.3.2 CRISPR-Based Diagnostic Platforms | |
  3. 3.3.3 Data Monetization Through Connected Diagnostics | |
  4. 3.3.4 Emerging-Market TB and AMR Programs | |
  5. 3.3.5 Direct-to-Consumer Home Molecular Testing |
4. 3.4 Industry Value Chain Analysis |
5. 3.5 Porter's Five Forces Analysis
4 Global Point of Care Molecular Diagnostics Market Size & Forecast (2021–2035) |
1. 4.1 Historical Market Size (2021–2025) |
2. 4.2 Current & Forecast Market Size (2026–2035) |
3. 4.3 Market Size by Revenue (USD Billion) |
4. 4.4 Year-over-Year Growth Analysis
5 Segmentation Analysis |
1. 5.1 By Product & Service | |
  1. 5.1.1 Assays & Kits | |
  2. 5.1.2 Instruments / Analyzers | |
  3. 5.1.3 Software & Services |
2. 5.2 By Application | |
  1. 5.2.1 Infectious Diseases | |
  2. 5.2.2 Oncology | |
  3. 5.2.3 Genetic Testing | |
  4. 5.2.4 Other Applications |
3. 5.3 By Technology | |
  1. 5.3.1 PCR-Based | |
  2. 5.3.2 INAAT | |
  3. 5.3.3 Other Technologies |
4. 5.4 By End User | |
  1. 5.4.1 Hospitals | |
  2. 5.4.2 Homecare Settings | |
  3. 5.4.3 Physician Offices / Clinics | |
  4. 5.4.4 Pharmacies & Retail Clinics | |
  5. 5.4.5 Other End Users
6 Regional Analysis |
1. 6.1 North America | |
  1. 6.1.1 United States | |
  2. 6.1.2 Canada | |
  3. 6.1.3 Mexico |
2. 6.2 Europe | |
  1. 6.2.1 Germany | |
  2. 6.2.2 United Kingdom | |
  3. 6.2.3 France | |
  4. 6.2.4 Italy | |
  5. 6.2.5 Spain | |
  6. 6.2.6 Nordic Countries | |
  7. 6.2.7 Russia | |
  8. 6.2.8 Rest of Europe |
3. 6.3 Asia-Pacific | |
  1. 6.3.1 China | |
  2. 6.3.2 India | |
  3. 6.3.3 Japan | |
  4. 6.3.4 South Korea | |
  5. 6.3.5 ASEAN | |
  6. 6.3.6 Rest of Asia-Pacific |
4. 6.4 South America | |
  1. 6.4.1 Brazil | |
  2. 6.4.2 Argentina | |
  3. 6.4.3 Rest of South America |
5. 6.5 Middle East & Africa | |
  1. 6.5.1 Saudi Arabia | |
  2. 6.5.2 UAE | |
  3. 6.5.3 South Africa | |
  4. 6.5.4 Egypt | |
  5. 6.5.5 Rest of MEA
7 Competitive Landscape |
1. 7.1 Market Share Analysis (2025) |
2. 7.2 Competitive Benchmarking Matrix |
3. 7.3 Company Profiles | |
  1. 7.3.1 Cepheid (Danaher Corporation) | |
  2. 7.3.2 Abbott Laboratories | |
  3. 7.3.3 Roche Diagnostics | |
  4. 7.3.4 Hologic, Inc. | |
  5. 7.3.5 bioMérieux SA | |
  6. 7.3.6 Becton, Dickinson and Company | |
  7. 7.3.7 Qiagen N.V. | |
  8. 7.3.8 Meridian Bioscience | |
  9. 7.3.9 Binx Health | |
  10. 7.3.10 Visby Medical
8 Future Outlook & Strategic Recommendations (2026–2035) |
1. 8.1 AI-Driven Instrument Intelligence and Predictive QC |
2. 8.2 Platform Consolidation and Razor-Blade Economics |
3. 8.3 Molecular Testing for Antimicrobial Stewardship |
4. 8.4 Sustainability and Cartridge Waste Reduction
9 Recent Developments & News
10 Frequently Asked Questions (FAQs)
11 Report Scope & Methodology |
1. 11.1 Study Period & Base Year |
2. 11.2 Data Sources & Citations |
3. 11.3 Abbreviations
12 LIST OF TABLES |
TABLE 1 Global Point of Care Molecular Diagnostics Market Size & Forecast, by Revenue (USD Billion), 2021–2035 |
TABLE 2 Global Point of Care Molecular Diagnostics Market — Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Market Driver Impact Analysis, 2026–2035 |
TABLE 4 Market Restraint Impact Analysis, 2026–2035 |
TABLE 5 Regional Market Summary, 2025 |
TABLE 6 North America Point of Care Molecular Diagnostics Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 7 Europe Point of Care Molecular Diagnostics Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 8 Asia-Pacific Point of Care Molecular Diagnostics Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 9 South America Point of Care Molecular Diagnostics Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 10 Middle East & Africa Point of Care Molecular Diagnostics Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 11 Global Point of Care Molecular Diagnostics Market Size, by Product & Service, 2021–2035 (USD Billion) |
TABLE 12 Global Point of Care Molecular Diagnostics Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 13 Global Point of Care Molecular Diagnostics Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 14 Global Point of Care Molecular Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 15 Competitive Benchmarking Matrix — Global Point of Care Molecular Diagnostics Market, 2025 |
TABLE 16 Company Profiles — Key Players, Point of Care Molecular Diagnostics Market |
TABLE 17 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 18 North America Point of Care Molecular Diagnostics Market Size, by Product & Service, 2021–2035 (USD Billion) |
TABLE 19 North America Point of Care Molecular Diagnostics Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 20 North America Point of Care Molecular Diagnostics Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 21 North America Point of Care Molecular Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 22 Europe Point of Care Molecular Diagnostics Market Size, by Product & Service, 2021–2035 (USD Billion) |
TABLE 23 Europe Point of Care Molecular Diagnostics Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 24 Europe Point of Care Molecular Diagnostics Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 25 Europe Point of Care Molecular Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 26 Asia-Pacific Point of Care Molecular Diagnostics Market Size, by Product & Service, 2021–2035 (USD Billion) |
TABLE 27 Asia-Pacific Point of Care Molecular Diagnostics Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 28 Asia-Pacific Point of Care Molecular Diagnostics Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 29 Asia-Pacific Point of Care Molecular Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 30 South America Point of Care Molecular Diagnostics Market Size, by Product & Service, 2021–2035 (USD Billion) |
TABLE 31 South America Point of Care Molecular Diagnostics Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 32 South America Point of Care Molecular Diagnostics Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 33 South America Point of Care Molecular Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 34 Middle East & Africa Point of Care Molecular Diagnostics Market Size, by Product & Service, 2021–2035 (USD Billion) |
TABLE 35 Middle East & Africa Point of Care Molecular Diagnostics Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 36 Middle East & Africa Point of Care Molecular Diagnostics Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 37 Middle East & Africa Point of Care Molecular Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 38 United States Point of Care Molecular Diagnostics Market Size, by Product & Service, 2021–2035 (USD Billion) |
TABLE 39 United States Point of Care Molecular Diagnostics Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 40 United States Point of Care Molecular Diagnostics Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 41 United States Point of Care Molecular Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 42 Canada Point of Care Molecular Diagnostics Market Size, by Product & Service, 2021–2035 (USD Billion) |
TABLE 43 Canada Point of Care Molecular Diagnostics Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 44 Canada Point of Care Molecular Diagnostics Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 45 Canada Point of Care Molecular Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 46 Mexico Point of Care Molecular Diagnostics Market Size, by Product & Service, 2021–2035 (USD Billion) |
TABLE 47 Mexico Point of Care Molecular Diagnostics Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 48 Mexico Point of Care Molecular Diagnostics Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 49 Mexico Point of Care Molecular Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 50 Germany Point of Care Molecular Diagnostics Market Size, by Segment, 2021–2035 (USD Billion) |
TABLE 51 United Kingdom Point of Care Molecular Diagnostics Market Size, by Segment, 2021–2035 (USD Billion) |
TABLE 52 France Point of Care Molecular Diagnostics Market Size, by Segment, 2021–2035 (USD Billion) |
TABLE 53 Italy Point of Care Molecular Diagnostics Market Size, by Segment, 2021–2035 (USD Billion) |
TABLE 54 Spain Point of Care Molecular Diagnostics Market Size, by Segment, 2021–2035 (USD Billion) |
TABLE 55 China Point of Care Molecular Diagnostics Market Size, by Product & Service, 2021–2035 (USD Billion) |
TABLE 56 China Point of Care Molecular Diagnostics Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 57 China Point of Care Molecular Diagnostics Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 58 China Point of Care Molecular Diagnostics Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 59 India Point of Care Molecular Diagnostics Market Size, by Segment, 2021–2035 (USD Billion) |
TABLE 60 Japan Point of Care Molecular Diagnostics Market Size, by Segment, 2021–2035 (USD Billion) |
TABLE 61 South Korea Point of Care Molecular Diagnostics Market Size, by Segment, 2021–2035 (USD Billion) |
TABLE 62 Brazil Point of Care Molecular Diagnostics Market Size, by Segment, 2021–2035 (USD Billion) |
TABLE 63 Saudi Arabia Point of Care Molecular Diagnostics Market Size, by Segment, 2021–2035 (USD Billion) |
TABLE 64 UAE Point of Care Molecular Diagnostics Market Size, by Segment, 2021–2035 (USD Billion) |
TABLE 65 South Africa Point of Care Molecular Diagnostics Market Size, by Segment, 2021–2035 (USD Billion) |
TABLE 66 Egypt Point of Care Molecular Diagnostics Market Size, by Segment, 2021–2035 (USD Billion) |
TABLE 67 Detailed Sources and Citations |
TABLE 68 Report Scope and Methodology Summary
13 LIST OF FIGURES |
FIGURE 1 Point of Care Molecular Diagnostics Market Dynamics — Drivers, Restraints, and Opportunities |
FIGURE 2 Industry Value Chain Analysis — Point of Care Molecular Diagnostics Market |
FIGURE 3 Porter's Five Forces Analysis — Point of Care Molecular Diagnostics Market |
FIGURE 4 Global Point of Care Molecular Diagnostics Market Size Trend (USD Billion), 2021–2035 |
FIGURE 5 Point of Care Molecular Diagnostics Market Share, by Product & Service, 2025 |
FIGURE 6 Point of Care Molecular Diagnostics Market Share, by Application, 2025 |
FIGURE 7 Point of Care Molecular Diagnostics Market Share, by Technology, 2025 |
FIGURE 8 Point of Care Molecular Diagnostics Market Share, by End User, 2025 |
FIGURE 9 Point of Care Molecular Diagnostics Market Share, by Region, 2025 |
FIGURE 10 North America Point of Care Molecular Diagnostics Market Size Trend, 2021–2035 |
FIGURE 11 Europe Point of Care Molecular Diagnostics Market Size Trend, 2021–2035 |
FIGURE 12 Asia-Pacific Point of Care Molecular Diagnostics Market Size Trend, 2021–2035 |
FIGURE 13 South America Point of Care Molecular Diagnostics Market Size Trend, 2021–2035 |
FIGURE 14 Middle East & Africa Point of Care Molecular Diagnostics Market Size Trend, 2021–2035 |
FIGURE 15 Competitive Landscape — Market Share Analysis, 2025 |
FIGURE 16 Competitive Benchmarking Radar — Top 10 Players

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
Product & Service	Assays & Kits; Instruments / Analyzers; Software & Services	Assays & Kits	Instruments / Analyzers
Application	Infectious Diseases; Oncology; Genetic Testing; Other Applications	Infectious Diseases	Oncology
Technology	PCR-Based; INAAT; Other Technologies	PCR-Based	INAAT
End User	Hospitals; Homecare Settings; Physician Offices / Clinics; Pharmacies & Retail Clinics; Other End Users	Hospitals	Homecare Settings
Geography	North America; Europe; Asia-Pacific; South America; Middle East & Africa	North America	Asia-Pacific

Market Segmentation Overview

By Product & Service

Sub-Segment	Key Trend
Assays & Kits	Multiplex panels with 5+ targets drive recurring consumable revenue
Instruments / Analyzers	Compact, CLIA-waived platforms reduce footprint and operator complexity
Software & Services	Cloud analytics and remote instrument monitoring enable predictive maintenance

Assays and kits generate the majority of recurring revenue in the Point of Care Molecular Diagnostics Market, as each installed analyzer consumes proprietary cartridges across a multi-year service lifecycle. Instrument innovation focuses on shrinking device footprint and simplifying operator workflows to enable deployment in non-traditional settings such as pharmacies and schools.

By Application

Sub-Segment	Key Trend
Infectious Diseases	Syndromic respiratory and STI panels remain the highest-volume use case
Oncology	Liquid-biopsy companion diagnostics approaching POC form factors
Genetic Testing	Pharmacogenomic pre-prescription screening gaining regulatory support
Other Applications	Transplant monitoring and prenatal screening entering pilot programs

Infectious diseases dominate clinical utilization, but oncology applications represent the highest-growth adjacency as circulating tumor DNA assays transition from reference-lab exclusivity to compact analyzer platforms capable of same-visit results.

By Technology

Sub-Segment	Key Trend
PCR-Based	Gold-standard sensitivity with established regulatory pathways worldwide
INAAT	Low-power, instrument-free amplification suited to field and LMIC deployment
Other Technologies	CRISPR-based detection and microarray approaches in clinical-trial stages

PCR-based systems maintain their dominance through extensive clinical-evidence libraries and broad regulatory clearance, while isothermal amplification technologies are closing the performance gap and expanding access in electricity-constrained environments.

By End User

Sub-Segment	Key Trend
Hospitals	Emergency departments and ICUs anchor the highest testing volumes
Homecare Settings	FDA de novo clearances for at-home molecular devices creating a new consumer channel
Physician Offices / Clinics	CLIA-waiver expansion enabling test adoption in primary care
Pharmacies & Retail Clinics	Scope-of-practice legislation broadening pharmacist-administered testing
Other End Users	Military, correctional, and field-deployment applications growing steadily

Hospitals remain the primary consumption channel, but home-care and pharmacy settings are the fastest-growing end-user segments as regulatory clearances and expanded scope-of-practice legislation enable molecular testing outside traditional clinical environments.

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”